581813-17-4

Basic information

• Product Name: 3-Bromo-4-(trifluoromethyl)benzoic acid
• Synonyms: 3-Bromo-4-(trifluoromethyl)benzoic acid;2-Bromo-4-carboxybenzotrifluoride, 3-Bromo-alpha,alpha,alpha-trifluoro-p-toluic acid;3-Bromo-4-(trifluoromethyl)benzoic acid 97%
• CAS NO: 581813-17-4
• Molecular Formula: C₈H₄BrF₃O₂
• Molecular Weight: 269
• Mol File: 581813-17-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 292.764 °C at 760 mmHg
• Flash Point: 130.859 °C
• Appearance: /
• Density: 1.774 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.30±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-4-(trifluoromethyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-4-(trifluoromethyl)benzoic acid(581813-17-4)
• EPA Substance Registry System: 3-Bromo-4-(trifluoromethyl)benzoic acid(581813-17-4)

Safety Data

• Hazardous Substances Data: 581813-17-4(Hazardous Substances Data)

Usage

General Description

3-Bromo-4-(trifluoromethyl)benzoic acid is a chemical compound with the molecular formula C8H4BrF3O2. It is a member of the benzoic acid family and contains a bromine atom and a trifluoromethyl group. 3-Bromo-4-(trifluoromethyl)benzoic acid is mainly used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical products. It is also used in chemical research and as an intermediate in organic synthesis. 3-Bromo-4-(trifluoromethyl)benzoic acid is a white crystalline solid that is sparingly soluble in water but soluble in organic solvents. It is important to handle this chemical with care and follow proper safety protocols when working with it.

InChI:InChI=1S/C8H4BrF3O2/c9-6-3-4(7(13)14)1-2-5(6)8(10,11)12/h1-3H,(H,13,14)

Upstream product

• 126541-81-9 methyl 3-nitro-4-(trifluoromethyl)benzoate 
• 2363-16-8 methyl 4-bromo-3-nitrobenzoate 
• 586-76-5 4-Bromobenzoic acid 
• 6319-40-0 4-bromo-3-nitrobenzoic acid 
• 126541-82-0 3-Amino-4-(trifluormethyl)benzoesaeure-methylester 
• 116965-16-3 3-nitro-4-(trifluoromethyl)benzoic acid 
• 125483-00-3 3-amino-4-(trifluoromethyl)benzoic acid 

Downstream Products

• 581813-18-5 3-bromo-4-(trifluoromethyl)benzamide 
• 581813-19-6 3-bromo-4-(trifluoromethyl)benzylamine 
• 1383618-46-9 6-ethoxy-2-(3-(pyridin-2-yl)-4-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin 
• 1383625-02-2 2-bromo-1-(3-bromo-4-(trifluoromethyl)phenyl)ethanone 

Relevant articles and documents

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.